<DOC>
	<DOCNO>NCT00628810</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving combination chemotherapy together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study side effect give combination chemotherapy together bevacizumab see well work treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Bevacizumab Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate objective response ( RECIST criterion ) 6 month associate FOLFIRI bevacizumab therapy . - Evaluate tolerability ( NCI CTC v. 2.0 criterion ) treatment . Secondary - Evaluate progression-free survival overall survival . - Determine time treatment failure . - Evaluate quality life ( EuroQOL EQ5D questionnaire ) . - Explore prognostic factor associate tolerability efficacy treatment . OUTLINE : This multicenter study . Patients stratify accord genotype ( UCT1A1*1/ UCT1A1*1 v UCT1A1*1/ UCT1A1*28 ) . Patients receive bevacizumab IV 30-90 minute , irinotecan hydrochloride IV 90 minute , leucovorin calcium IV 2 hour , fluorouracil IV 46 hour day 1 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Quality life assess baseline , every 4 course , every 2 month completion study therapy . After completion study therapy , patient follow every 2-3 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic adenocarcinoma colon rectum Not curable surgery Genotype UGT1A1*1/UGT1A1*1 UGT1A1*1/ UGT1A1*28 Measurable disease No original tumor place No secondary cerebral metastasis PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 02 Life expectancy ≥ 3 month Absolute neutrophil count ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 9.0 g/dL Total bilirubin ≤ 1.5 time normal Alkaline phosphatase ≤ 2.5 time normal ( 5 time normal liver involvement ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Progressive gastrointestinal ulcer , hemorrhagic ulcer , perforation past 6 month Enteropathy chronic diarrhea Proteinuria &gt; 500 mg/24 hour Active cardiac disease Uncontrolled hypertension Myocardial infarction past 12 month Angina NYHA grade IIIV congestive heart disease Severe arrhythmia even treatment Peripheral vascular disease ≥ grade II Nonhealing wound , ulcer , severe bone fracture Hemorrhagic diatheses coagulopathy Severe uncontrolled infection Severe uncontrolled medical condition Other malignant disease past 5 year except curatively treat basal cell skin cancer carcinoma situ uterine cervix Severe traumatic injury within past 4 week PRIOR CONCURRENT THERAPY : No prior chemotherapy metastatic disease One prior regimen chemotherapy neoadjuvant adjuvant set original tumor allow At least 6 month since prior chemotherapy No prior irinotecan hydrochloride bevacizumab No oral parenteral anticoagulant therapy within past 10 day Warfarin allow provide INR &lt; 1.5 No major surgery biopsy within past 4 week No puncture past 7 day No planned major surgery No concurrent daily chronic aspirin ( &gt; 325 mg/day ) , antiinflammatories , steroids No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>